Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $11.6M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Exicure Hitron Inc. | 10% Owner | Jan 21 '26 | Sale | $4.50 | 258,367 | $1,162,652 | 1,598,947 | Jan 21 12:46 PM |
| Exicure Hitron Inc. | 10% Owner | Jan 16 '26 | Sale | $4.50 | 734,747 | $3,306,362 | 1,857,314 | Jan 20 02:09 PM |
Company profile
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Exicure Hitron Inc. | 10% Owner | Jan 07 '26 | Sale | $4.50 | 741,272 | $3,335,724 | 2,592,061 | Jan 08 08:42 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.